EVIDENCE LIBRARY
Naloxone Dispensing Surveillance Used Benzodiazepine Co-Use as Risk Context, Not a Reversal Target
A U.S. pharmacy report examined naloxone access and discussed concurrent benzodiazepine use within opioid overdose-risk assessment.
A U.S. pharmacy report examined naloxone access and discussed concurrent benzodiazepine use within opioid overdose-risk assessment.
What the report counted
The analysis covered retail dispensing during 2012–2018. Naloxone dispensing rose substantially, with marked geographic differences. In 2018 there was one naloxone prescription per 69 high-dose opioid prescriptions, a denominator concerning high-dose opioid dispensing rather than benzodiazepine prescriptions.
Access data do not establish an individual rescue outcome
A dispensed product may not be present or administered at a later event. The report does not show how much naloxone a particular mixed-exposure patient needed or whether it reversed every cause of reduced responsiveness. Its discussion of benzodiazepine co-use should not be converted into a claim that naloxone directly treats benzodiazepine effects. This historical surveillance study measures distribution patterns, not a benzodiazepine-specific antidote trial or current legal requirements.
Source paper
Original analysis of the supplied journal article, identified as PMC6687198.